Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …

Liver cancer is the fifth most common cancer and the second leading cause of malignant
death in Asia, and Asia reports 72.5% of the world's cases in 2020. As the most common …

PURPOSE Lenvatinib (LEN) is a first-line therapy for patients with advanced hepatocellular
carcinoma (HCC); however, it has shown modest survival benefits. Therefore, we aimed to …

PURPOSE Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil,
leucovorin, and oxaliplatin (HAIC-FO) displayed an encouraging safety profile and antitumor …

Importance Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality,
and additional first-line treatments are needed. The programmed cell death protein 1 …

Background: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but
prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the second
leading cause of cancer-related mortality worldwide. This review is an updated version that …

Hepatocellular carcinoma is the most common type of malignant tumour in Asia. Treatment
is decided according to the staging system with information on tumour burden and liver …

Classically activated M1 macrophages and alternatively activated M2 macrophages are two
polarized subsets of macrophages at the extreme ends of a constructed continuum. In the …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide and is increasing in incidence. Local ablative therapy plays a leading role in HCC …